INTERVIEW: Unravelling The Strategies Behind Sanofi's China Surge
This article was originally published in PharmAsia News
Executive Summary
The figures are screaming for attention. While many multinationals are grappling with lower single-digit growth in China, Sanofi logged a 20% increase last year, despite the country’s overall economic downturn. The figure was testament to the French group’s creative approaches to county-level opportunities and integrated disease management in a market filled with complexities and uncertainties. Sanofi Pharma China GM Jean-Christophe Pointeau shares some of the secrets in an exclusive interview.
You may also be interested in...
China Biotech Podcast: BIOSECURE Updates, Genmab/ProfoundBio Deal
In this mixed Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Pashadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed BIOSECURE Act in the US Congress and US-China biotech movements. Also discussed is how Chinese biotechs are becoming acquisition targets for overseas biotech companies, including the recent purchases of Profound by Genmab and AnHeart Theraputics by Nuvantion.
BIOSECURE: What’s Coming Next?
The potential impact of the BIOSECURE Act continues to spread as the Biden administration increases its focus on China. But with BIO's top lobbyist and the top House sponsor of the legislation now headed out the door, the future of the bill remains uncertain.
China Implements Data Transfer Regulation, With Some Waivers
A newly enacted regulation in China governing the overseas transfer of data allows waivers under certain conditions but also introduces some new hurdles compared to the draft version.